A Real-world Study of DEXYCU in the Treatment of Inflammation After Cataract Surgery
Phase 4
Completed
- Conditions
- InflammationCataract
- Interventions
- Drug: Dexycu
- First Posted Date
- 2024-07-12
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Ocumension Therapeutics (Shanghai) Co., Ltd
- Target Recruit Count
- 263
- Registration Number
- NCT06497699
- Locations
- 🇨🇳
Boao Super Hospital, Bo'ao, China
🇨🇳Hainan Traditional Chinese Medicine Hospital, Haikou, Hainan, China
Study of OT202 in Treating Moderate to Severe Dry Eye
Phase 2
Completed
- Conditions
- Dry Eye
- Interventions
- Drug: PlaceboDrug: OT202 conc 0.1%Drug: OT202 conc 0.5%
- First Posted Date
- 2024-05-30
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Ocumension Therapeutics (Shanghai) Co., Ltd
- Target Recruit Count
- 213
- Registration Number
- NCT06435182
- Locations
- 🇨🇳
The Third Xiangya Hospital Of Central South University, Changsha, China
🇨🇳The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China
🇨🇳Tianjin Eye Hospital, Tianjin, China
Study of Dexycu in Treating Intraocular Inflammation
Phase 3
Completed
- Conditions
- InflammationCataract
- Interventions
- Drug: DexycuDrug: Placebo
- First Posted Date
- 2024-05-24
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- Ocumension Therapeutics (Shanghai) Co., Ltd
- Target Recruit Count
- 285
- Registration Number
- NCT06429306
- Locations
- 🇨🇳
Shanghai General Hospital, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath